{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:08:54Z","timestamp":1792084134265,"version":"4.4.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002721","name":"Charcot-Marie-Tooth Association","doi-asserted-by":"publisher","award":["SR-202310"],"award-info":[{"award-number":["SR-202310"]}],"id":[{"id":"10.13039\/100002721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ebiom.2026.106294","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:09:47Z","timestamp":1778764187000},"page":"106294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Progress and challenges in intrathecal gene therapy for neurological disorders"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3903-1299","authenticated-orcid":false,"given":"Alexia","family":"Kagiava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleopas A.","family":"Kleopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2026.106294_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of intrathecal AAV9 gene therapy for giant axonal neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymthe.2023.11.014","article-title":"Combination HSCT and intravenous AAV-mediated gene therapy in a canine model proves pivotal for translation of Krabbe disease therapy","volume":"32","author":"Bradbury","year":"2024","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106294_bib3","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ymthe.2021.01.026","article-title":"Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease","volume":"29","author":"Heller","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2026.106294_bib4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.omtm.2020.04.012","article-title":"Translational feasibility of lumbar puncture for intrathecal AAV administration","volume":"17","author":"Hinderer","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ebiom.2026.106294_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2023.07.011","article-title":"Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy","volume":"30","author":"Kagiava","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10\u201311","key":"10.1016\/j.ebiom.2026.106294_bib6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41434-021-00250-0","article-title":"AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy","volume":"28","author":"Kagiava","year":"2021","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106294_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021130","article-title":"Gene therapy in ALS and SMA: advances, challenges and perspectives","volume":"24","author":"Lejman","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib9","article-title":"Gene therapy for Spinal Muscular Atrophy (SMA): a review of current challenges and safety considerations for onasemnogene abeparvovec (Zolgensma)","volume":"15","author":"Ogbonmide","year":"2023","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106294_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137159","article-title":"AAV9-mediated FIG4 delivery prolongs life span in Charcot-Marie-Tooth disease type 4J mouse model","volume":"131","author":"Presa","year":"2021","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1016\/j.ebiom.2026.106294_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159814","article-title":"A translatable RNAi-driven gene therapy silences PMP22\/Pmp22 genes and improves neuropathy in CMT1A mice","volume":"132","author":"Stavrou","year":"2022","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106294_bib12","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol Ther"},{"issue":"1\u20132","key":"10.1016\/j.ebiom.2026.106294_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/hum.2021.069","article-title":"The AAV9 variant capsid AAV-F mediates widespread transgene expression in nonhuman primate spinal cord after intrathecal administration","volume":"33","author":"Beharry","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ebiom.2026.106294_bib14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106294_bib15","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/j.ymthe.2023.09.018","article-title":"Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice","volume":"31","author":"Cheng","year":"2023","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.24332","article-title":"A large animal model of spinal muscular atrophy and correction of phenotype","volume":"77","author":"Duque","year":"2015","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106294_bib17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther"},{"key":"10.1016\/j.ebiom.2026.106294_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human Alpha-L-Iduronidase in rhesus macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106294_bib19","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1172\/JCI130600","article-title":"Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models","volume":"129","author":"Morelli","year":"2019","journal-title":"J Clin Invest"},{"issue":"3\u20134","key":"10.1016\/j.ebiom.2026.106294_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41434-021-00231-3","article-title":"AAV1.NT-3 gene therapy for X-linked charcot-marie-tooth neuropathy type 1","volume":"29","author":"Ozes","year":"2022","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11011-020-00630-2","article-title":"Crossing the blood-brain barrier with AAV vectors","volume":"36","author":"Liu","year":"2021","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.ebiom.2026.106294_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146832","article-title":"Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies","volume":"1739","author":"Bailey","year":"2020","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/humc.2017.231","article-title":"AAVrh.10-Mediated APOE2 central nervous system gene therapy for APOE4-Associated Alzheimer's Disease","volume":"29","author":"Rosenberg","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/genes15010031","article-title":"The efficacy of a human-ready miniMECP2 gene therapy in a pre-clinical model of Rett syndrome","volume":"15","author":"Sadhu","year":"2023","journal-title":"Genes (Basel)"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106294_bib25","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1016\/j.ymthe.2023.08.020","article-title":"AAV9-mediated SH3TC2 gene replacement therapy targeted to Schwann cells for the treatment of CMT4C","volume":"31","author":"Georgiou","year":"2023","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02694-1","article-title":"Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery","volume":"11","author":"Kagiava","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/hum.2017.026","article-title":"Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106294_bib28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/hmg\/ddq514","article-title":"Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice","volume":"20","author":"Dominguez","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106294_bib29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/hmg\/ddad202","article-title":"Long term peripheral AAV9-SMN gene therapy promotes survival in a mouse model of spinal muscular atrophy","volume":"33","author":"Reilly","year":"2024","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ebiom.2026.106294_bib30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omtm.2017.04.007","article-title":"Development of a novel AAV gene therapy cassette with improved safety features and efficacy in a mouse model of Rett syndrome","volume":"5","author":"Gadalla","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106294_bib31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106294_bib32","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase I ascending-dose study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106294_bib34","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","article-title":"Intrathecal gene therapy for giant axonal neuropathy","volume":"390","author":"Bharucha-Goebel","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/sj.mt.6300394","article-title":"Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells","volume":"16","author":"Hargrove","year":"2008","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106294_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146286","article-title":"AAV9\/MFSD8 gene therapy is effective in preclinical models of neuronal ceroid lipofuscinosis type 7 disease","volume":"132","author":"Chen","year":"2022","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106294_bib37","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1038\/s41591-025-03822-4","article-title":"Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1\/2 trial","volume":"31","author":"Eichler","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2026.106294_bib38","article-title":"First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trial","volume":"123","author":"Greenberg","year":"2025","journal-title":"EBioMedicine"},{"issue":"23\u201324","key":"10.1016\/j.ebiom.2026.106294_bib39","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune responses and immunosuppressive strategies for adeno-associated virus-based gene therapy for treatment of central nervous system disorders: current knowledge and approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106294_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101631","article-title":"Should patients with pre-existing anti-AAV antibodies be excluded from receiving intrathecally delivered AAV vectors?","volume":"33","author":"Gray","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106294_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101602","article-title":"Impact of pre-existing immunity on safety and biodistribution of a single AAV9 vectorintrathecal injection in cynomolgus monkeys","volume":"33","author":"Vono","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0733-8619(01)00016-0","article-title":"Inherited neuropathies","volume":"20","author":"Kleopa","year":"2002","journal-title":"Neurol Clin"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106294_bib43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0092-8674(91)90613-4","article-title":"DNA duplication associated with Charcot-Marie-Tooth disease type 1A","volume":"66","author":"Lupski","year":"1991","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.ebiom.2026.106294_bib44","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1523\/JNEUROSCI.17-23-09077.1997","article-title":"Altered trafficking of mutant connexin32","volume":"17","author":"Deschenes","year":"1997","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106294_bib45","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/jnr.10255","article-title":"Cellular mechanisms of connexin32 mutations associated with CNS manifestations","volume":"68","author":"Kleopa","year":"2002","journal-title":"J Neurosci Res"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106294_bib46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1471-4159.2000.740711.x","article-title":"Analysis of gap junction assembly using mutated connexins detected in Charcot-Marie-Tooth X-linked disease","volume":"74","author":"Martin","year":"2000","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106294_bib47","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0896-6273(00)80973-3","article-title":"Changes in permeability caused by connexin 32 mutations underlie X-linked Charcot-Marie-Tooth disease","volume":"19","author":"Oh","year":"1997","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/nbdi.2002.0545","article-title":"Diverse trafficking abnormalities of connexin32 mutants causing CMTX","volume":"11","author":"Yum","year":"2002","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib49","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/jns.12175","article-title":"Screening for SH3TC2 gene mutations in a series of demyelinating recessive Charcot-Marie-Tooth disease (CMT4)","volume":"21","author":"Piscosquito","year":"2016","journal-title":"J Peripher Nerv Syst"},{"issue":"23","key":"10.1016\/j.ebiom.2026.106294_bib50","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1093\/hmg\/ddp427","article-title":"Missense mutations in the SH3TC2 protein causing Charcot-Marie-Tooth disease type 4C affect its localization in the plasma membrane and endocytic pathway","volume":"18","author":"Lupo","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"7149","key":"10.1016\/j.ebiom.2026.106294_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature05876","article-title":"Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J","volume":"448","author":"Chow","year":"2007","journal-title":"Nature"},{"issue":"Pt 8","key":"10.1016\/j.ebiom.2026.106294_bib52","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/brain\/awn114","article-title":"Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration","volume":"131","author":"Zhang","year":"2008","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106294_bib53","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1086\/375039","article-title":"Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V","volume":"72","author":"Antonellis","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106294_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tins.2009.11.001","article-title":"GARS axonopathy: not every neuron's cup of tRNA","volume":"33","author":"Motley","year":"2010","journal-title":"Trends Neurosci"},{"issue":"18","key":"10.1016\/j.ebiom.2026.106294_bib55","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/hmg\/ddh222","article-title":"Characterization of Ighmbp2 in motor neurons and implications for the pathomechanism in a mouse model of human spinal muscular atrophy with respiratory distress type 1 (SMARD1)","volume":"13","author":"Grohmann","year":"2004","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106294_bib56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/jns.12539","article-title":"Recent advances in the treatment of charcot-marie-tooth neuropathies","volume":"28","author":"Bolino","year":"2023","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib57","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1038\/s41467-021-22593-3","article-title":"AAV2\/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A","volume":"12","author":"Gautier","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106294_bib58","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.24441","article-title":"Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease","volume":"78","author":"Sargiannidou","year":"2015","journal-title":"Ann Neurol"},{"issue":"17","key":"10.1016\/j.ebiom.2026.106294_bib59","doi-asserted-by":"crossref","first-page":"E2421","DOI":"10.1073\/pnas.1522202113","article-title":"Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy","volume":"113","author":"Kagiava","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106294_bib60","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/hmg\/ddy056","article-title":"Intrathecal gene therapy in mouse models expressing CMT1X mutations","volume":"27","author":"Kagiava","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"21","key":"10.1016\/j.ebiom.2026.106294_bib61","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/hmg\/ddz199","article-title":"Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X","volume":"28","author":"Kagiava","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106294_bib62","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/brain\/awz064","article-title":"Gene replacement therapy in a model of charcot-marie-tooth 4C neuropathy","volume":"142","author":"Schiza","year":"2019","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106294_bib63","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/mt.2016.33","article-title":"Rescue of a mouse model of spinal muscular atrophy with respiratory distress type 1 by AAV9-IGHMBP2 is dose dependent","volume":"24","author":"Shababi","year":"2016","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s43856-025-00734-9","article-title":"Preclinical use of a clinically-relevant scAAV9\/SUMF1 vector for the treatment of multiple sulfatase deficiency","volume":"5","author":"Presa","year":"2025","journal-title":"Commun Med (Lond)"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib65","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymthe.2024.11.029","article-title":"Dorsal root ganglion toxicity after AAV intra-CSF delivery of a RNAi expression construct into non-human primates and mice","volume":"33","author":"Hawley","year":"2025","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106294_bib66","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1089\/hum.2018.079","article-title":"Intrathecal adeno-associated viral vector-mediated gene delivery for adrenomyeloneuropathy","volume":"30","author":"Gong","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106294_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101354","article-title":"An in vitro and in vivo efficacy evaluation of gene therapy candidate SBT101 in mouse models of adrenomyeloneuropathy and in NHPs","volume":"32","author":"Vasireddy","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41434-024-00498-2","article-title":"Expression and distribution of rAAV9 intrathecally administered in juvenile to adolescent mice","volume":"32","author":"Garza","year":"2025","journal-title":"Gene Ther"},{"key":"10.1016\/j.ebiom.2026.106294_bib69","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.omtm.2022.10.004","article-title":"AAVrh10 vector corrects pathology in animal models of GM1 gangliosidosis and achieves widespread distribution in the CNS of nonhuman primates","volume":"27","author":"Hocquemiller","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101168","article-title":"Intrathecal delivery of a bicistronic AAV9 vector expressing beta-hexosaminidase A corrects Sandhoff disease in a murine model: a dosage study","volume":"32","author":"Ryckman","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106294_bib71","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/jnr.23882","article-title":"Intrathecal administration of AAV\/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant","volume":"94","author":"Karumuthil-Melethil","year":"2016","journal-title":"J Neurosci Res"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib72","doi-asserted-by":"crossref","DOI":"10.1172\/JCI182235","article-title":"AAV9\/SLC6A1 gene therapy rescues abnormal EEG patterns and cognitive behavioral deficiencies in Slc6a1-\/- mice","volume":"135","author":"Guo","year":"2024","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102479","article-title":"Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S","volume":"36","author":"Smieszek","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106294_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164575","article-title":"Intrathecal AAV9\/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies","volume":"133","author":"Chen","year":"2023","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106294_bib75","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/mt.2014.135","article-title":"Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I","volume":"22","author":"Hinderer","year":"2014","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106294_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119204","article-title":"Safety and efficacy of intravenous and intrathecal delivery of AAV9-Mediated ARSA in minipigs","volume":"24","author":"Mullagulova","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106294_bib77","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41434-020-00203-z","article-title":"Intra-cisterna magna delivery of an AAV vector with the GLUT1 promoter in a pig recapitulates the physiological expression of SLC2A1","volume":"28","author":"Nakamura","year":"2021","journal-title":"Gene Ther"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106294_bib78","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1172\/JCI133953","article-title":"Krabbe disease successfully treated via monotherapy of intrathecal gene therapy","volume":"130","author":"Bradbury","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2026.106294_bib79","doi-asserted-by":"crossref","DOI":"10.1172\/JCI182942","article-title":"Five-year analysis of efficacy and safety of a bidirectional AAV gene therapy in Tay-Sachs sheep","volume":"135","author":"Taghian","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2026.106294_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.762209","article-title":"Pilot study assessing the impact of intrathecal administration of variants AAV-PHP.B and AAV-PHP.eB on brain transduction in adult rhesus macaques","volume":"9","author":"Arotcarena","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"issue":"15\u201316","key":"10.1016\/j.ebiom.2026.106294_bib81","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-associated virus-induced dorsal root ganglion pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ebiom.2026.106294_bib82","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.omtm.2022.01.013","article-title":"Characterization of AAV-mediated dorsal root ganglionopathy","volume":"24","author":"Buss","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"465","key":"10.1016\/j.ebiom.2026.106294_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau6414","article-title":"Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques","volume":"10","author":"Borel","year":"2018","journal-title":"Sci Transl Med"},{"issue":"13\u201314","key":"10.1016\/j.ebiom.2026.106294_bib84","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1089\/hum.2021.255","article-title":"Single-dose intrathecal dorsal root ganglia toxicity of onasemnogene abeparvovec in cynomolgus monkeys","volume":"33","author":"Tukov","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106294_bib85","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and MicroRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106294_bib86","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/s41591-024-03078-4","article-title":"AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient","volume":"30","author":"Dowling","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00568","article-title":"A dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1X","volume":"22","author":"Christou","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib88","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/81701","article-title":"The gene encoding gigaxonin, a new member of the cytoskeletal BTB\/kelch repeat family, is mutated in giant axonal neuropathy","volume":"26","author":"Bomont","year":"2000","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib89","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1086\/518902","article-title":"The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter","volume":"81","author":"Siintola","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106294_bib90","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40263-019-00620-8","article-title":"Current and emerging treatment strategies for neuronal ceroid lipofuscinoses","volume":"33","author":"Kohlschutter","year":"2019","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106294_bib91","first-page":"2929","article-title":"Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia","volume":"143","author":"Ebrahimi-Fakhari","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib92","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ajhg.2009.06.004","article-title":"Mutation in the AP4M1 gene provides a model for neuroaxonal injury in cerebral palsy","volume":"85","author":"Verkerk","year":"2009","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106294_bib93","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0092-8674(03)00347-7","article-title":"Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme","volume":"113","author":"Dierks","year":"2003","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106294_bib94","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/jimd.12298","article-title":"Natural history of multiple sulfatase deficiency: retrospective phenotyping and functional variant analysis to characterize an ultra-rare disease","volume":"43","author":"Adang","year":"2020","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106294_bib95","doi-asserted-by":"crossref","first-page":"e1233","DOI":"10.1542\/peds.2011-0078","article-title":"Natural history of infantile G(M2) gangliosidosis","volume":"128","author":"Bley","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib96","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41591-019-0674-1","article-title":"Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS","volume":"26","author":"Bravo-Hernandez","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2026.106294_bib97","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.omtm.2022.12.012","article-title":"Neurofilament light chain and dorsal root ganglia injury after adeno-associated virus 9 gene therapy in nonhuman primates","volume":"28","author":"Johnson","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106294_bib98","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","article-title":"Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit","volume":"24","author":"Van Alstyne","year":"2021","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib99","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106294_bib100","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106294_bib101","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106294_bib102","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (Onasemnogene Abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106294_bib103","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106294_bib104","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/hum.2014.011","article-title":"Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy","volume":"25","author":"Passini","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106294_bib105","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy","volume":"120","author":"Passini","year":"2010","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106294_bib106","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/01926233221101309","article-title":"Intrathecal sc-AAV9-CB-GFP: systemic distribution predominates following single-dose administration in cynomolgus macaques","volume":"50","author":"Meseck","year":"2022","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ebiom.2026.106294_bib107","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-025-04103-w","article-title":"Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial","volume":"32","author":"Proud","year":"2025","journal-title":"Nat Med"},{"issue":"27","key":"10.1016\/j.ebiom.2026.106294_bib108","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1073\/pnas.0603765103","article-title":"Effective gene therapy in an authentic model of Tay-Sachs-related diseases","volume":"103","author":"Cachon-Gonzalez","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106294_bib109","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/mt.2012.44","article-title":"Gene transfer corrects acute GM2 gangliosidosis--potential therapeutic contribution of perivascular enzyme flow","volume":"20","author":"Cachon-Gonzalez","year":"2012","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106294_bib110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for Tay-Sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106294_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115240","article-title":"Amyotrophic lateral sclerosis: pathophysiological mechanisms and treatment strategies (part 2)","volume":"26","author":"Tolochko","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426001763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426001763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:58:33Z","timestamp":1783151913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426001763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":111,"alternative-id":["S2352396426001763"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106294","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress and challenges in intrathecal gene therapy for neurological disorders","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106294"}}